Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes

NCT01455857 is registered in ClinicalTrials.gov with Intarcia Therapeutics as lead sponsor.

NCT NCT01455857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes
Lead sponsor
Intarcia Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2013
Completion date
September 30, 2014
Enrollment
460 (actual)
Sites
121

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes